Paper Review Records
全部论文审稿周期
14 篇有效样本 · 按发表日期由新到旧排列
审稿天数=录用日期-收稿日期；保留 PDF/DOI/网页源链接
55
天
End-of-life care values and treatment preferences among Japanese breast cancer patients and families: A dyadic cross-sectional study
作者
Akemi Hara; Ayu Ajitomi; Kazunoshin Tachibana; Kenji Gonda; Masahiro Wada; Rui Omori; Megumi Arai; Kayoko Konuma; Toyoaki Sawano; Yoshiaki Kanemoto; Hirotomo Miyatake; Tomohiro Kurokawa; Yukiko Kouchi; Norio Kanzaki; Yasuhiro Kotera; Yoshitake Takebayashi; Michio Murakami; Tohru Ohtake; Hiroaki Shimmura; Akihiko Ozaki展开收起
作者单位
Clinical Research Center, Jyoban Hospital of Tokiwa Foundation, Iwaki, Japan; Department of Biostatistics, The University of North Carolina at Chapel Hill, Chapel Hill, North Cartolina, USA; Breast and Thyroid Center, Jyoban Hospital of Tokiwa Foundation, Iwaki, Japan; Department of Breast Surgery, Fukushima Medical University School of Medicine, Fukushima, Japan; Department of Breast Surgery, Utsunomiya Central Clinic, Utsunomiya, Japan; Department of Breast Cancer, St. Luke's International Hospital, Tokyo, Japan; Department of Nursing, Jyoban Hospital of Tokiwa Foundation, Iwaki, Japan; Department of Surgery, Jyoban Hospital of Tokiwa Foundation, Iwaki, Japan; Yushoukai Medical Corporation Nobishiroclinic, Fujisawa, Japan; Department of Urology, Jyoban Hospital of Tokiwa Foundation, Iwaki, Japan; School of Health Sciences, Institute of Mental Health, University of Nottingham, Nottingham, United Kingdom; Department of Health Risk Communication, Fukushima Medical University School of Medicine, Fukushima, Japan; Center for Infectious Disease Education and Research, The University of Osaka, Suita, Japan; EIPM Center, The University of Osaka, Suita, Japan展开收起
56
天
Beyond safety: rethinking concomitant radiotherapy and trastuzumab deruxtecan in metastatic breast cancer — from feasibility to precision practice
作者
Yueting Tan; Benyuan Cheng; Kun He; Xiaobing Xie展开收起
作者单位
Hunan University of Chinese Medicine, Changsha, Hunan, 410208, China; The First Hospital of Hunan University of Chinese Medicine, Changsha, Hunan, 410007, China展开收起
207
天
Molecular and immune profiling of HER2-low, HER2 ultra-low, and HER2-null male breast cancer
作者
Dario Trapani; Sachin Kumar Deshmukh; Sharon Wu; Joanne Xiu; Priya Jayachandran; Shipra Gandhi; Nancy U. Lin; Giuseppe Curigliano; Philip M. Spanheimer; Daniel L. Abravanel; Milan Radovich; Maryam Lustberg; Stephanie L. Graff; George W. Sledge; Sara M. Tolaney; José P. Leone展开收起
作者单位
Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA; Caris Life Sciences, Phoenix, AZ, USA; El Camino Hospital, Mountain View, CA, USA; Winship Cancer Institute, Emory University, Atlanta, GA, USA; European Institute of Oncology, IRCCS, Milan, Italy; Department of Oncology and Hemato-Oncology, University of Milano, Milano, Italy; University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; Yale School of Medicine, Yale University, New Haven, CT, USA; Lifespan Cancer Institute, Legorreta Cancer Center, Brown University, Providence, RI, USA展开收起
66
天
Local treatment for HER2-positive or triple negative second ipsilateral breast cancer event: A propensity score-matched analysis of the GEC-ESTRO database
作者
J.M. Hannoun-Levi; J. Gal; C. Weltens; V. Smanyko; D. Kauer-Domer; D. Pasquier; C. Lemanski; S. Racadot; G. Houvenaeghel; B. Guix; A. Belliere-Calandry; K. Loessl; B. Polat; C. Gutierrez; R. Galalae; C. Polgar; R. Schiappa; V. Strnad展开收起
作者单位
Department of Radiation Oncology, Antoine Lacassagne Cancer Centre, University of Côte d’Azur, Nice, France; University Côte d’Azur, Institut Hospitalo-Universitaire (IHU) RespirERA, 27 Rue du Professeur Delvalle, Nice, 06000, France; Department of Radiation Oncology, Radiation Oncology, University Hospital Gasthuisberg, Leuven, Belgium; Centre of Radiotherapy, National Institute of Oncology, Budapest, Hungary; Department of Radiation Oncology, Medical University of Vienna, Vienna, Austria; Department of Radiation Oncology, Oscar Lambret Cancer Centre, Lille University, Lille, France; Department of Radiation Oncology, Montpellier Cancer Institute, Montpellier, France; Department of Radiation Oncology, Leon Berard Cancer Centre, Lyon, France; Department of Surgical Oncology, Paoli-Calmettes Cancer Institute, Marseille, France; Department of Radiation Oncology, Medical Institute for Radiotherapy & Oncology, Barcelona, Spain; Department of Radiation Oncology, Auvergne Jean Perrin Cancer Centre, Clermont-Ferrand, France; Department of Radiation Oncology, Radiation Oncology, Inselspital, Bern University Hospital, Switzerland; Department of Radiation Oncology, Wurzburg University, Wurzburg, Germany; Department of Radiation Oncology, Hospital del Mar, Brachytherapy Unite, Catalan Institute of Oncology, Barcelona, Spain; MedAustron Centre for Ion Therapy and Research, Wiener Neustadt, Austria; Radiotherapy Centre, National Institute of Oncology, Budapest, Hungary; Department of Radiotherapy, Semmelweis University, Budapest, Hungary; Department of Radiation Oncology, Erlangen University Hospital, Erlangen, Germany展开收起
307
天
The genomic landscape of HER2 negative metastatic breast cancer with loss of estrogen and progesterone receptors
作者
Ilenia Migliaccio; Marta Paoli; Chiara Biagioni; Cristina Guarducci; Francesca Galardi; Giulia Anichini; Laura Biganzoli; Matteo Benelli; Luca Malorni展开收起
作者单位
Translational Research Unit, Department of Oncology, Hospital of Prato, Azienda USL Toscana Centro, Italy; Department of Cellular, Computational and Integrative Biology, University of Trento, Trento, Italy; Department of Oncology, Hospital of Prato, Azienda USL Toscana Centro, Italy; Department of Experimental and Clinical Biomedical Sciences “Mario Serio”, University of Florence, Florence, Italy展开收起
140
天
Prediction of benefit from docetaxel chemotherapy for HR-positive breast cancer in the PACS-01 trial
作者
Frédérique Penault-Llorca; Amelie Lusque; Thomas Filleron; Kevin Tran; Lili Du; Rick Baehner; Florence Dalenc; Magali Lacroix-Triki; Thomas Bachelot; Fabrice Andre; Pascal Boucher; Jérôme Lemonnier; W. Fraser Symmans展开收起
作者单位
Department of Biopathology, Centre Jean Perrin, Université Clermont Auvergne, INSERM, U1240 Imagerie Moléculaire et Stratégies Théranostiques, Clermont Ferrand, F-63000, France; Biostatistics & Health Data Science Unit, University of Toulouse, Oncopole Claudius Regaud, IUCT-Oncopole, Toulouse, France; Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA; Exact Sciences, Madison, WI, USA; Department of Pathology, University of California, San Francisco, CA, USA; Department of Medical Oncology, Oncopole Claudius Regaud, Institut Universitaire du Cancer Toulouse-Oncopole, Toulouse, France; Department of Pathology, Institut Gustave Roussy, Villejuif, France; Department of Medical Oncology, Centre Leon Berard, Lyon, France; Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France; Unicancer, Paris, France展开收起
Expert Matching · Case Demo
把投稿要求，转成可验证的期刊方案
说清专业、时限和作者背景，CrushSCI 结合真实审稿样本，给出拟题方向、期刊初筛与周期判断。
客户询问
我是环境工程专业，需要一篇 SCI，希望 3 个月内见刊。没有基金，也没有大牛挂名，可以投哪些期刊？
CrushSCI回复
可以。先按 90 天时限做可行性筛选，同步查找无基金、无知名作者挂靠的典型论文案例，作为选刊依据。重点核对研究质量与期刊 scope。
- 拟题建议
- 《融合机器学习与生命周期评价的城市污水处理碳排放预测与优化》
样本口径2026 年最近 5 篇有效论文样本
平均审稿62 天
中位数65 天